American Society of Clinical Oncology 2021 Annual Meeting Highlights for Radiation Oncologists
- PMID: 35071828
- PMCID: PMC8767256
- DOI: 10.1016/j.adro.2021.100779
American Society of Clinical Oncology 2021 Annual Meeting Highlights for Radiation Oncologists
Abstract
The annual meeting of the American Society of Clinical Oncology is the largest multidisciplinary oncology-focused conference in the world. With more than 4900 total abstracts in 2021 alone, it is difficult for individuals to evaluate all the results. This article presents a review of 32 selected abstracts across all disease sites, focusing on those of greatest relevance to radiation oncologists.
© 2021 The Authors.
References
-
- Vicini F, Shah C, Whitworth PW, et al. A novel biosignature identifies DCIS patients with a poor biologic subtype with an unacceptably high rate of local recurrence after breast conserving surgery and radiotherapy. J Clin Oncol. 2021;39 513-513.
-
- Sun K, Ensor JE, Xu Y, et al. A phase II trial of stereotactic radiation therapy and in situ oncolytic virus therapy in metastatic triple-negative breast cancer (mTNBC) patients followed by pembrolizumab (STOMP) J Clin Oncol. 2021;39 1079-1079.
-
- Roth P, Gorlia T, Reijneveld JC, et al. EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with temozolomide-based radiochemotherapy versus temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma. J Clin Oncol. 2021;39:2004.
-
- Qian DC, Marascio JA, Neill SG, et al. Gene expression signature to predict radiation response in lower-grade gliomas. J Clin Oncol. 2021;39:2019.
Publication types
LinkOut - more resources
Full Text Sources